PPARG and cancer: Furthermore, several studies have demonstrated the efficacy of PPAR-γ agonists in inhibiting the survival of cancer stem cells (CSCs) derived from human cell lines or specimens from breast, prostate, colon, bladder, and blood tissues (129–134) supporting a role of PPAR-γ in regulating CSC biology.